Clinical trials: Advanced or Metastatic Non-small Cell Lung Cancer
- Condition Advanced or Metastatic Non-small Cell Lung Cancer
- Funder type Industry (pharma, biotech, devices)
Solid Tumor, MET Alteration
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
- Trial name
- NCT06669117
- Testing
- VERT-002
- Where
- 19 sites in United States, Belgium and 7 more
- Volunteers
- 140 people
- Sponsor
- Pierre Fabre Medicament
Non-Small Cell Lung Cancer
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
The primary objective of the study is to compare overall survival of participants randomized to receiving custirsen in combination with docetaxel with participants randomized to receive docetaxel alone.
- Trial name
- ENSPIRIT (NCT01630733)
- Testing
- Custirsen, Docetaxel
- Where
- 78 sites in United States, Australia and 12 more
- Volunteers
- 664 people
- Sponsor
- Achieve Life Sciences
Non-small Cell Lung Cancer
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic…
- Trial name
- NCT04656652
- Testing
- DS-1062a, Docetaxel
- Where
- 209 sites in United States, Argentina and 24 more
- Volunteers
- 605 people
- Sponsor
- Daiichi Sankyo
Carcinoma, Non-Small-Cell Lung
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with…
- Trial name
- PAPILLON (NCT04538664)
- Testing
- Amivantamab, Pemetrexed, Carboplatin
- Where
- 232 sites in United States, Australia and 24 more
- Volunteers
- 308 people
- Sponsor
- Janssen Research & Development, LLC
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Metastatic Non Small Cell Lung Cancer
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer…
- Trial name
- TROPION-Lung08 (NCT05215340)
- Testing
- Datopotamab Deruxtecan, Pembrolizumab
- Where
- 234 sites in United States, Argentina and 26 more
- Volunteers
- 740 people
- Sponsor
- Daiichi Sankyo
Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 as a monotherapy or in…
- Conditions
- Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06747585
- Testing
- ALE.P02, Pembrolizumab
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 235 people
- Sponsor
- Alentis Therapeutics AG
Non-squamous Non-small-cell Lung Cancer
A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer
This trial is a randomized, double-blind, parallel-controlled, multicenter phase III clinical study. To evaluate the clinical efficacy of SIBP04 in patients with locally advanced, metastatic or recurrent non-squamous non-small…
- Trial name
- NCT05318443
- Testing
- SIBP04, Avastin, Paclitaxel
- Where
- China
- Volunteers
- 512 people
- Sponsor
- Shanghai Institute Of Biological Products
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)
This prospective, double-blind, randomized study will evaluate the safety and efficacy of two dose levels of erlotinib [Tarceva] on progression-free survival, response and disease control rates and overall survival in patients…
- Trial name
- NCT01183858
- Testing
- Erlotinib [Tarceva]
- Where
- 63 sites in China, Denmark and 7 more
- Volunteers
- 315 people
- Sponsor
- Hoffmann-La Roche
KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
The study is being conducted to evaluate the efficacy, and safety of HRS-7058 in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
- Trial name
- NCT07601048
- Testing
- HRS-7058, Fulzerasib Tablets, Garsorasib Tablets
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Non Squamous, Non-small-cell Lung Cancer
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
This study is to determine if the combination regimen of tivantinib with erlotinib will improve overall survival relative to erlotinib alone in subjects with locally advanced or metastatic non-squamous, non-small cell lung cancer…
- Trial name
- NCT01244191
- Testing
- Tivantinib, Erlotinib
- Where
- 304 sites in United States, Argentina and 21 more
- Volunteers
- 1,048 people
- Sponsor
- Daiichi Sankyo
Local Advanced or Metastatic NSCLC
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations
This is a multicenter, randomized, open-label, parallel-controlled phase 3 study. This study aims to evaluate the efficacy and safety of JMT101 combined with Osimertinib compared with Cisplatin combined with pemetrexed in…
- Trial name
- NCT06380348
- Testing
- JMT101 Injection, Osimertinib tablet, Cisplatin injection
- Volunteers
- 398 people
- Sponsor
- Shanghai JMT-Bio Inc.
Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
This research study is studying an investigational drug, NC318, as a possible treatment for subjects with advanced or metastatic non-small cell lung cancer in combination with chemotherapy
- Trial name
- NCT04430933
- Testing
- NC318, Pemetrexed/Carboplatin, Nab paclitaxel/Carboplatin
- Sponsor
- NextCure, Inc.
Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy.
- Trial name
- NCT05635708
- Testing
- Tislelizumab, BGB-A445, LBL-007
- Where
- 61 sites in United States, Australia and 13 more
- Volunteers
- 418 people
- Sponsor
- BeiGene
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur.
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04032704
- Testing
- ladiratuzumab vedotin, pembrolizumab
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 205 people
- Sponsor
- Seagen Inc.
Non-Small Cell Lung Cancer
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
This 3 arm study will compare the efficacy and safety of three different dermatological creams designed for prophylaxis of skin rash associated with Tarceva treatment in patients with locally advanced or metastatic non-small cell…
- Trial name
- NCT00718315
- Testing
- erlotinib [Tarceva], fusidic acid [Verutex], erythromycin [Eritex]
- Where
- 26 sites in Brazil
- Volunteers
- 201 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)
This observational study will investigate the efficacy and tolerability of Vargatef (Nintedanib) plus docetaxel in daily routine second-line treatment in patients with locally advanced, metastatic or locally recurrent NSCLC.
- Trial name
- NCT02392455
- Testing
- treatment
- Where
- Germany
- Volunteers
- 817 people
- Sponsor
- Boehringer Ingelheim
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that…
- Conditions
- Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
- Trial name
- NCT05014815
- Testing
- Ociperlimab, Tislelizumab, Carboplatin
- Where
- 64 sites in United States, Australia and 6 more
- Volunteers
- 272 people
- Sponsor
- BeiGene
Carcinoma, Non-Small-Cell Lung
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
Primary objective of the trial is to evaluate the safety of afatinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR (Epidermal growth factor receptor) mutation(s) and have never…
- Trial name
- NCT01953913
- Testing
- Afatinib
- Where
- 33 sites in China, Hong Kong and 3 more
- Volunteers
- 542 people
- Sponsor
- Boehringer Ingelheim
Nonsmall Cell Lung Cancer
A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC
This is a Phase 1/2, open-label, multicenter study of HS-10296 with dose escalation, dose expansion and extension cohorts in locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients who have progressed following…
- Trial name
- NCT02981108
- Testing
- HS-10296
- Where
- 10 sites in United States
- Volunteers
- 364 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.